MapLight Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed July 31, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 8/100
What the filing says
This is a standard Schedule 13D/A amendment disclosing directors and officers of Novo Holdings A/S and the Novo Nordisk Foundation—the entities making a filing regarding MapLight Therapeutics. The document lists 11 officers/directors of Novo Holdings (including CEO Kasim Kutay and CFO Nigel Govett) and 11 of the Novo Nordisk Foundation (including CEO Mads Krogsgaard Thomsen). No dollar amounts, transaction details, stake percentages, or changes to MapLight's business are disclosed in this exhibit.
Why this rating
Routine disclosure of counterparty governance. Contains no MapLight-specific financial, operational, or shareholding detail; purely administrative Schedule 13D/A documentation.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.